On September 29, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, reported that it has submitted an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration ("FDA") for Teverelix, its investigational, next generation, long-acting GnRH antagonist, in advanced prostate cancer ("APC") patients at increased cardiovascular ("CV") risk.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The submission is designed to establish a defined, capital-efficient and partner-ready registrational pathway for Teverelix without Medicus independently funding an additional clinical development study in the APC program at this time. Importantly, the proposed design is stage-gated: it begins with approximately 80 randomized patients, incorporating and replacing the previously FDA-cleared stand-alone 40-patient open-label Phase 2b dose-optimization study. Once predefined continuation criteria have been satisfied, the program would then proceed to add approximately 528 patients, for approximately 608 patients in total, with eligible patients from the initial stage contributing to the final registration analyses.

If the FDA agrees with the proposed approach, Medicus believes the optimized design could reduce the overall planned clinical development program from approximately 1,500 patients to approximately 600 patients while providing a single pathway encompassing dose optimization, androgen suppression and prospective evaluation of cardiovascular differentiation in APC patients at increased cardiovascular risk, without an upfront commitment to enroll the full study population.

Following FDA feedback, and subject to the nature of that feedback, Medicus’ intent is to seek to out-license or otherwise strategically partner the Teverelix APC program rather than independently fund execution of the proposed registrational study.

There can be no assurance that the FDA will agree with the proposed protocol, that the optimized development pathway will ultimately support registration, or that Medicus will successfully enter into a licensing or other strategic transaction involving Teverelix.

Management Commentary

"Our objective with this submission is not to commit Medicus capital to another APC clinical study-it is to define the most efficient registrational pathway possible and make Teverelix ready for a strategic partner," stated Dr. Raza Bokhari, Executive Chairman and CEO of Medicus. "The FDA previously cleared a 40-patient open-label dose-optimization study. Rather than independently funding that study, we have now proposed an approximately 600-patient seamless registration-intent program that incorporates a more rigorous 80-patient randomized dose-optimization stage and could reduce the overall development population from ~ 1,500 patients to ~ 600 and is more likely to be partner-ready."

Designed to Reach Partner Readiness Without Additional Medicus R&D Spend

The submission represents a further implementation of the Company’s capital-efficient portfolio strategy announced on September 8, 2026, under which Medicus is concentrating capital and organizational resources on programs where focused clinical development may offer the most compelling risk-adjusted opportunity.

Medicus’ objective with the current FDA submission is to complete the regulatory optimization of the Teverelix APC development pathway before committing additional internal capital to clinical execution.

If the FDA provides constructive feedback on the proposed approach, Medicus intends to use the resulting regulatory-defined development pathway as the basis for strategic partnering discussions and seek a pharmaceutical partner to fund and execute subsequent APC clinical development and commercialization

From FDA-Cleared Dose Optimization to a Seamless Registration-Intent Program

On February 10, 2026, Medicus announced that FDA had provided "Study May Proceed" clearance for a 40-patient open-label Phase 2b dose-optimization study of Teverelix in men with advanced prostate cancer appropriate for androgen deprivation therapy. That study was designed to confirm the Teverelix dosing regimen and sustained testosterone suppression.

In addition to focusing its efforts towards GMP grade manufacturing, quality-release, and other clinical study readiness steps, which are anticipated to be completed before the end of this year, the Company continued to optimize the APC development strategy. The newly submitted protocol proposes an approximately 80-patient randomized dose-optimization stage as the first part of an approximately 608-patient seamless Phase 2b/3 registration-intent study. Subject to predefined criteria, the study would then continue with approximately 528 additional patients, with eligible patients from the initial stage contributing to the final registration analyses.

The proposed design is intended to avoid conducting a stand-alone dose-optimization study followed by a separate, substantially larger Phase 3 program. Compared with a previously discussed development approach involving approximately 1,500 patients, the seamless strategy could reduce total planned enrollment by approximately 60% while reducing duplication, time and capital requirements associated with sequential studies.

Cardiovascular-Focused Registrational Strategy

The optimized strategy incorporates emerging randomized clinical evidence published in JAMA Cardiology in 2026 showing that differences in coronary plaque progression between GnRH treatment pathways can be objectively measured over 12 months using non-invasive coronary CT angiography ("CCTA"). CCTA can be incorporated into a multicenter study using standardized scans at baseline and Month 12 with blinded central quantitative analysis.

The proposed protocol combines established testosterone-suppression requirements with a 12-month coronary non-calcified plaque endpoint, while allowing longer-term cardiovascular event follow-up to continue in the same patients. The development strategy is designed to evaluate whether Teverelix can achieve effective androgen deprivation while demonstrating cardiovascular differentiation in advanced prostate cancer patients already at increased CV risk.

If the FDA agrees that this approach could support registration, Medicus believes the proposed design could provide a substantially shorter and more capital-efficient development pathway than the previously contemplated sequential program. Any development timeline remains subject to FDA feedback, successful study execution, enrollment, clinical results and regulatory review.

About Teverelix

Teverelix is an investigational next-generation, long-acting GnRH antagonist formulated as a microcrystalline suspension. Unlike GnRH agonists, which induce an initial testosterone surge, Teverelix provides immediate receptor antagonism, enabling rapid suppression of luteinizing hormone, follicle-stimulating hormone and downstream sex hormones without flare. Medicus is evaluating Teverelix across hormone-dependent indications and is pursuing a capital-efficient development strategy intended to advance programs through regulatory and clinical value-creating milestones while evaluating strategic partnership opportunities.

(Press release, Medicus Pharma, SEP 29, 2026, https://medicuspharma.com/medicus-pharma-submits-optimized-teverelix-registrational-protocol-to-fda-to-create-partner-ready-program-in-advanced-prostate-cancer/ [SID1234671151])